Sorry, no content matched your criteria.
Featured Story
Ebola Stocks Surge as Race for Treatment Heats Up - but Steer Clear of Overhyped Plays
The number of companies racing to find an Ebola treatment is increasing. All drugs remain in the testing stage, but that hasn't stopped investors from piling into these "Ebola stocks."
Chimerix (Nasdaq: CMRX) climbed 5% Monday on reports that the Ebola patient in Dallas is being treated with its drug, brincidofovir.
The number of companies racing to find an Ebola treatment is increasing. All drugs remain in the testing stage, but that hasn't stopped investors from piling into these "Ebola stocks."
Chimerix (Nasdaq: CMRX) climbed 5% Monday on reports that the Ebola patient in Dallas is being treated with its drug, brincidofovir.